Literature DB >> 7266632

Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.

J Lindenbaum, D G Rund, V P Butler, D Tse-Eng, J R Saha.   

Abstract

In approximately 10 per cent of patients given digoxin, substantial conversion of the drug to cardioinactive, reduced metabolites (digoxin reduction products, or DRPs) occurs. The site and clinical importance of this conversion is unknown. In four normal volunteers taking digoxin daily for four weeks, urinary excretion of DRPs was greatest after a poorly absorbed tablet was ingested, and least after intravenous administration, Stool cultures from subjects known to make DRPs in vivo ("excretors") converted digoxin to DRPs; cultures from nonexcretors did not. Three excretors were given tablets for 22 to 29 days. A five-day course of erythromycin or tetracycline, administered after a base-line period of 10 to 17 days, markedly reduced or eliminated DRP excretion in urine and stool. Serum digoxin concentrations rose as much as twofold after antibiotics were given. We conclude that in some persons digoxin is inactivated by gastrointestinal bacteria. Changes in the enteric flora may markedly alter the state of digitalization.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7266632     DOI: 10.1056/NEJM198110013051403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  88 in total

1.  Metabolism of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, by intestinal microorganisms.

Authors:  I Sasaki; T Tamura; T Shibakawa; T Fujita; M Murakami; A Yamamoto; S Muranishi
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 2.  Challenges Associated with Route of Administration in Neonatal Drug Delivery.

Authors:  Matthew W Linakis; Jessica K Roberts; Anita C Lala; Michael G Spigarelli; Natalie J Medlicott; David M Reith; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 3.  Xenobiotics: Interaction with the Intestinal Microflora.

Authors:  Kun Lu; Ridwan Mahbub; James G Fox
Journal:  ILAR J       Date:  2015

4.  Community health care: therapeutic opportunities in the human microbiome.

Authors:  Justin L Sonnenburg; Michael A Fischbach
Journal:  Sci Transl Med       Date:  2011-04-13       Impact factor: 17.956

Review 5.  Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?

Authors:  Lingeng Lu; Yixing Wu; Lingjun Zuo; Xingguang Luo; Peter J Large
Journal:  World J Microbiol Biotechnol       Date:  2013-10-09       Impact factor: 3.312

6.  Pharmacological Activation of PXR and CAR Downregulates Distinct Bile Acid-Metabolizing Intestinal Bacteria and Alters Bile Acid Homeostasis.

Authors:  Joseph L Dempsey; Dongfang Wang; Gunseli Siginir; Qiang Fei; Daniel Raftery; Haiwei Gu; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

7.  Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring.

Authors:  Ian D Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

Review 8.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

9.  Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.

Authors:  Jens Rengelshausen; Christoph Göggelmann; Jürgen Burhenne; Klaus-Dieter Riedel; Jochen Ludwig; Johanna Weiss; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 10.  Developing a metagenomic view of xenobiotic metabolism.

Authors:  Henry J Haiser; Peter J Turnbaugh
Journal:  Pharmacol Res       Date:  2012-08-09       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.